...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Trends in immunology >Targeting Tumor-Associated Macrophages in Cancer
【24h】

Targeting Tumor-Associated Macrophages in Cancer

机译：针对癌症的肿瘤相关巨噬细胞

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Macrophages are phagocytes that serve as a first line of defense against pathogenic insults to tissues. These innate immune cells mount proinflammatory responses to pathogens and repair damaged tissues. However, tumor-associated macrophages (TAMs) express cytokines and chemokines that can suppress antitumor immunity and promote tumor progression. Preclinical studies have identified crucial pathways regulating the recruitment, polarization, and metabolism of TAMs during tumor progression. Moreover, novel therapeutics targeting these pathways can indirectly stimulate cytotoxic T cell activation and recruitment, and synergize with checkpoint inhibitors, chemotherapy and/or radiation therapy in preclinical studies. Thus, clinical trials with therapeutic agents that promote phagocytosis or suppress survival, proliferation, trafficking, or polarization of TAMs are currently underway. These early results offer the promise of improved cancer outcomes.
机译：巨噬细胞是吞噬细胞，作为对组织的致病性损伤的第一道防线。 这些天生的免疫细胞安装促炎反应对病原体和修复受损组织。 然而，肿瘤相关的巨噬细胞（TAMS）表达细胞因子和趋化因子，可以抑制抗肿瘤免疫力并促进肿瘤进展。 临床前研究已经确定了在肿瘤进展期间调节TAMS的募集，极化和代谢的关键途径。 此外，靶向这些途径的新疗法可以间接刺激细胞毒性T细胞活化和募集，并在临床前研究中促进检查点抑制剂，化疗和/或放射治疗。 因此，目前正在进行促进吞噬作用或抑制存活，增殖，贩运或两极分的治疗剂的临床试验。 这些早期结果提供了改善癌症结果的承诺。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号